5 terminated, 4 completed, 2 withdrawn, 1 active not recruiting. 8 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Terminated 2, Withdrawn 2, Active not recruiting 1 |
| Phase 3 | 4 | Terminated 3, Completed 1 |
| Phase 1 | 2 | Terminated 2 |
Follow Veru Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss Enobosarm, Semaglutide (Wegovy) weekly injection - Obesity & Overweight, Mobility Disability | Phase 2 | Active not recruiting | Veru Inc. | 239 | 2026-03-26 | 2026-09-04 |
| Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt Enobosarm, Semaglutide - Muscle Loss, Obesity | Phase 2 | Completed | Veru Inc. | 168 | 2024-04-29 | 2025-09-17 |
| Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer Sabizabulin, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator - Metastatic Breast Cancer | Phase 2 | Withdrawn | Veru Inc. | 2023-03-15 | 2023-03-24 | |
| Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant - Metastatic Breast Cancer | Phase 3 | Terminated | Veru Inc. | 5 | 2022-04-11 | 2024-02-26 |
| P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC . Sabizabulin, Sacituzumab Govitecan-hziy, Sabizabulin/Sacituzumab govitecan-hziy Combo - Metastatic Triple Negative Breast Cancer | Phase 2 | Withdrawn | Veru Inc. | 2021-12-30 | 2022-02-08 | |
| Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer Enobosarm, Exemestane - Metastatic Breast Cancer | Phase 3 | Terminated | Veru Inc. | 52 | 2021-10-12 | 2024-01-26 |
| Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent VERU-111, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | Phase 3 | Terminated | Veru Inc. | 105 | 2021-06-24 | 2024-02-05 |
| To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer VERU-100 - Advanced Prostate Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Veru Inc. | 24 | 2021-06-09 | 2023-05-19 |
| VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study VERU-111 - SARS-CoV Infection | Phase 3 | Completed | Veru Inc. | 204 | 2021-05-18 | 2026-09-10 |
| COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 Veru-111 - Respiratory Distress Syndrome, Adult | Phase 2 | Completed | Veru Inc. | 39 | 2020-06-18 | 2022-10-27 |
| To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer VERU-111 - Metastatic Castration Resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | Veru Inc. | 80 | 2019-01-18 | 2023-09-26 |
| Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer Veru-944, Placebo - Prostate Cancer Metastatic | Phase 2 | Completed | Veru Inc. | 93 | 2018-09-14 | 2021-12-03 |
Breast Neoplasms (3) · Obesity (2) · Bulbo-Spinal Atrophy, X-Linked (1) · Muscular Atrophy (1) · Overweight (1) · Prostatic Neoplasms, Castration-Resistant (1) · Respiratory Distress Syndrome (1) · Severe Acute Respiratory Syndrome (1) · Triple Negative Breast Neoplasms (1)
sabizabulin (6) · ostarine (4) · exemestane (3) · Everolimus (2) · semaglutide (2) · Abiraterone Acetate (1) · Fulvestrant (1) · Selective Estrogen Receptor Modulators (1) · Zuclomiphene (1) · abemaciclib (1) · abiraterone (1) · enzalutamide (1)
United States (11) · Argentina (1) · Brazil (1) · Bulgaria (1) · Colombia (1) · Mexico (1) · Poland (1) · Spain (1) · Ukraine (1)